Wednesday, February 17, 2016 9:57:35 AM
We employ our Ligand Activated Therapy (LAT) platform technology to create prodrugs in order to improve one or more of the attributes of approved drugs, such as susceptibility to abuse, bioavailability and safety.
Our most advanced product candidate, KP201/APAP, consists of KP201, our prodrug of hydrocodone, formulated in combination with acetaminophen (APAP). We are developing KP201/APAP as an immediate release (IR) product candidate for the treatment of acute moderate to moderately severe pain.
KP201/APAP was designed with abuse-deterrent properties to address the epidemic of opioid abuse in the United States. We designed KP201/APAP to deter tampering and abuse by selecting a molecular structure that prevents the release of the opioid upon crushing, physical manipulation and other commonly employed extraction techniques. We believe this approach to abuse-deterrence at the molecular level may be more effective than many formulation-based abuse-deterrence technologies, which combine the opioid drug with another drug or use an abuse-deterrent capsule or physical matrix.
In addition to KP201/APAP, KemPharm is building a pipeline of prodrug product candidates that target large market opportunities in pain, attention deficit hyperactivity disorder (ADHD) and other central nervous system indications.
Recent KMPH News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/25/2024 09:13:10 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 06/25/2024 09:11:32 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/29/2024 11:49:38 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/10/2024 08:23:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/10/2024 11:46:20 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/03/2024 08:17:44 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/03/2024 08:15:21 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 04/01/2024 09:27:49 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM